Warning message will be there |
Did you mean: nat rev drug discov jour
| All | Review |
| Items 1-20 of 1270 |
|
1 2 3 4 5 ... 64Next |
|
1:
|
Development trends for human monoclonal antibody therapeutics.
Nat Rev Drug Discov. 2010 Sep 3; [Epub ahead of print]
PMID: 20811384 [PubMed - as supplied by publisher]
|
|
2:
|
The therapeutic potential of carbon monoxide.
Nat Rev Drug Discov. 2010 Sep;9(9):728-43
PMID: 20811383 [PubMed - in process]
|
|
3:
|
Averting inflammation by targeting the cytokine environment.
Nat Rev Drug Discov. 2010 Sep;9(9):703-18
PMID: 20811382 [PubMed - in process]
|
|
4:
|
Emerging principles in protease-based drug discovery.
Nat Rev Drug Discov. 2010 Sep;9(9):690-701
PMID: 20811381 [PubMed - in process]
|
|
5:
|
Cancer: Lethal cycling.
Nat Rev Drug Discov. 2010 Sep;9(9):682
PMID: 20811380 [PubMed - in process]
|
|
6:
|
Target discovery: Blocking BTK in B-cell disorders.
Nat Rev Drug Discov. 2010 Sep;9(9):681
PMID: 20811379 [PubMed - in process]
|
|
7:
|
Antifungal drugs: Targeting histone acetylation.
Nat Rev Drug Discov. 2010 Sep;9(9):680-1
PMID: 20811378 [PubMed - in process]
|
|
8:
|
Biotechnology: Skin patch flu vaccine shows promise.
Nat Rev Drug Discov. 2010 Sep;9(9):680-1
PMID: 20811377 [PubMed - in process]
|
|
9:
|
Multiple sclerosis: Putting a dampener on inflammation.
Nat Rev Drug Discov. 2010 Sep;9(9):679
PMID: 20811376 [PubMed - in process]
|
|
10:
|
Cabazitaxel.
Nat Rev Drug Discov. 2010 Sep;9(9):677-8
PMID: 20811375 [PubMed - in process]
|
|
11:
|
The antibiotics market.
Nat Rev Drug Discov. 2010 Sep;9(9):675-6
PMID: 20811374 [PubMed - in process]
|
|
12:
|
Jim connolly.
Nat Rev Drug Discov. 2010 Sep;9(9):674
PMID: 20811373 [PubMed - in process]
|
|
13:
|
Patent watch.
Nat Rev Drug Discov. 2010 Sep;9(9):672-3
PMID: 20811372 [PubMed - in process]
|
|
14:
|
Deal watch: Harnessing creative risk sharing.
Nat Rev Drug Discov. 2010 Sep;9(9):671
PMID: 20811371 [PubMed - in process]
|
|
15:
|
Deal watch: Metabolex and Sanofi-Aventis partner on GPCR agonists for type 2 diabetes.
Nat Rev Drug Discov. 2010 Sep;9(9):670
PMID: 20811370 [PubMed - in process]
|
|
16:
|
Deal watch: Infinity and Intellikine to develop oral PI3K inhibitors for inflammatory diseases.
Nat Rev Drug Discov. 2010 Sep;9(9):670
PMID: 20811369 [PubMed - in process]
|
|
17:
|
Potential remains for PPAR-targeted drugs.
Nat Rev Drug Discov. 2010 Sep;9(9):668-9
PMID: 20811368 [PubMed - in process]
|
|
18:
|
Antibody-drug conjugates for cancer: poised to deliver?
Nat Rev Drug Discov. 2010 Sep;9(9):665-7
PMID: 20811367 [PubMed - in process]
|
|
19:
|
An insight into the antifungal pipeline: selected new molecules and beyond.
Nat Rev Drug Discov. 2010 Sep;9(9):719-27
PMID: 20725094 [PubMed - in process]
|
|
20:
|
The case for entrepreneurship in R&D in the pharmaceutical industry.
Nat Rev Drug Discov. 2010 Sep;9(9):683-9
PMID: 20725093 [PubMed - in process]
|
| Items 1-20 of 1270 |
|
1 2 3 4 5 ... 64Next |
Warning message will be there |
